再発性悪性神経膠腫(Recurrent Malignant Glioma)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Recurrent Malignant Glioma Overview 6
Therapeutics Development 7
Pipeline Products for Recurrent Malignant Glioma – Overview 7
Pipeline Products for Recurrent Malignant Glioma – Comparative Analysis 8
Recurrent Malignant Glioma – Therapeutics under Development by Companies 9
Recurrent Malignant Glioma – Therapeutics under Investigation by Universities/Institutes 10
Recurrent Malignant Glioma – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Recurrent Malignant Glioma – Products under Development by Companies 13
Recurrent Malignant Glioma – Products under Investigation by Universities/Institutes 14
Recurrent Malignant Glioma – Companies Involved in Therapeutics Development 15
Amgen Inc. 15
AstraZeneca PLC 16
Eisai Co., Ltd. 17
Nerviano Medical Sciences S.r.l. 18
Sanofi 19
Recurrent Malignant Glioma – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
cabazitaxel – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Carboxyamidotriazole Orotate – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
carmustine SR – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cell Therapy for Refractory Gliomas – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cell Therapy to Target IL-13 for Malignant Glioma – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Dendritic Cell Therapy for Oncology – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
disufenton sodium – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DNX-2401 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lenvatinib – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
milciclib – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rilotumumab – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Recurrent Malignant Glioma – Recent Pipeline Updates 51
Recurrent Malignant Glioma – Dormant Projects 56
Recurrent Malignant Glioma – Discontinued Products 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59